Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

P1800000

Pindolol

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

1-(1H-Indol-4-yloxy)-3-(isopropylamino)-2-propanol, 1-(1H-Indol-4-yloxy)-3-[(1-methylethyl)amino]-2-propanol

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C14H20N2O2
CAS Number:
13523-86-9
Molecular Weight:
248.32
MDL number:
MFCD00010530
UNSPSC Code:
41116107
PubChem Substance ID:
329820108
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

pindolol

manufacturer/tradename

EDQM

mp

167-171 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CC(C)NCC(O)COc1cccc2[nH]ccc12

InChI

1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3

InChI key

JZQKKSLKJUAGIC-UHFFFAOYSA-N

Gene Information

human ... ADRB1(153) , ADRB2(154)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Pindolol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

β1-adrenoceptor antagonist; putative 5-HT1A serotonin receptor agonist; vasodilator.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302,H315,H319,H335

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Drug therapy. Pindolol: a new beta-adrenoceptor antagonist with partial agonist activity.
W H Frishman
The New England journal of medicine, 308(16), 940-944 (1983-04-21)
Antihypertensive effects of pindolol.
L M Gonasun
American heart journal, 104(2 Pt 2), 374-387 (1982-08-01)
R McAskill et al.
The British journal of psychiatry : the journal of mental science, 173, 203-208 (1999-02-02)
Antidepressant therapy is not always effective and is slow to take effect. In theory, these shortfalls may be caused by induction of neuronal negative feedback via pre-synaptic 5-HTIA receptors. Pindolol, an antagonist at somatodentritic pre-synaptic 5-HTIA receptors has been investigated
H Duner
British journal of clinical pharmacology, 24 Suppl 1, 51S-54S (1987-01-01)
1. In recent years evidence has accumulated which indicates that although various beta-adrenoceptor antagonists are equally effective in lowering blood pressure in patients with essential hypertension the mechanisms of action of the different drugs are heterogeneous. 2. Pindolol, a beta-adrenoceptor
J S Olver et al.
The Australian and New Zealand journal of psychiatry, 34(1), 71-79 (2001-02-24)
To critically review the literature on clinical trials in which pindolol, a 5HT1A receptor antagonist, has been used to augment the effects of antidepressants in patients with depression and to examine the pharmacodynamics and pharmacokinetics that may underlie such augmentations.
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service